Zhang, X., Zhang, R., Chen, H., Wang, L., Ren, C., Pataer, A., . . . Fang, B. (2020). KRT-232 and navitoclax enhance trametinib’s anti-Cancer activity in non-small cell lung cancer patient-derived xenografts with KRAS mutations. Am J Cancer Res.
Stile di citazione ChicagoZhang, Xiaoshan, et al. "KRT-232 and Navitoclax Enhance Trametinib’s Anti-Cancer Activity in Non-small Cell Lung Cancer Patient-derived Xenografts With KRAS Mutations." Am J Cancer Res 2020.
Citazione MLAZhang, Xiaoshan, et al. "KRT-232 and Navitoclax Enhance Trametinib’s Anti-Cancer Activity in Non-small Cell Lung Cancer Patient-derived Xenografts With KRAS Mutations." Am J Cancer Res 2020.
Attenzione: Queste citazioni potrebbero non essere precise al 100%.